# Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

> **NCT01597050** · PHASE2 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 54 (actual)

## Conditions studied

- Lupus Erythematosus, Discoid
- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** R932333
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01597050
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2016-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01597050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01597050, "Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01597050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*